scispace - formally typeset
S

Szu-Min Hsieh

Researcher at National Taiwan University

Publications -  163
Citations -  3265

Szu-Min Hsieh is an academic researcher from National Taiwan University. The author has contributed to research in topics: Vaccination & Medicine. The author has an hindex of 29, co-authored 146 publications receiving 2822 citations.

Papers
More filters
Journal ArticleDOI

Impact of Chronic Hepatitis B Virus (HBV) Infection on Outcomes of Patients Infected with HIV in an Area Where HBV Infection Is Hyperendemic

TL;DR: Between June 1994 and February 2003, a total of 111 human immunodeficiency virus (HIV)-infected patients with chronic hepatitis B virus (HBV) coinfection and 387 HIV- Infected patients without HBV or hepatitis C virus coinfections were prospectively observed to assess the impact of HBV infection on outcomes of HIV- infected patients.
Journal ArticleDOI

Invasive amebiasis as an emerging parasitic disease in patients with human immunodeficiency virus type 1 infection in Taiwan.

TL;DR: People infected with HIV in Taiwan are at increased risk for invasive amebiasis and exhibit a relatively high frequency of elevated antibody titers and intestinal colonization with E histolytica.
Journal ArticleDOI

Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy.

TL;DR: The data indicated that virologic, immunologic, and clinical responses to HAART and prognosis of HIV-1-infected TB patients who were concurrently treated with antituberculous therapy and HAART were similar to those of non-TB patients.
Journal ArticleDOI

Impact of Hepatitis D Virus Infection on the Long-Term Outcomes of Patients with Hepatitis B Virus and HIV Coinfection in the Era of Highly Active Antiretroviral Therapy: A Matched Cohort Study

TL;DR: HDV infection increased risk of hepatitis flares, liver cirrhosis, hepatic decompensation, and death in patients with HBV-HIV coinfection, but did not affect clinical, virological, or immunologic responses to highly active antiretroviral therapy.